醫學新知
Update
無標題文件


首頁 > 醫學新知 > 醫學新知
Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women.
2017-03-23

Heart. 2017 Mar 11. pii: heartjnl-2016-310272.
doi: 10.1136/heartjnl-2016-310272. [Epub ahead of print]

Author

Sekiguchi H1,2,3,4, Shimamoto K5,3,6, Takano M5,3, Kimura M5,3, Takahashi Y5,3, Tatsumi F5,3, Watanabe E5,3, Jujo K3, Ishizuka N3,4, Kawana M5,6,3, Hagiwara N3.
 
Author information

1.Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan gucci_0418@yahoo.co.jp.
2.Cardiology, National Hospital Organization Yokohama Medical Center, Kanagawa, Japan.
3.Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
4.Cardiology, Institute of Geriatrics Tokyo Women's Medical University, Tokyo, Japan.
5.Cardiology, Aoyama Hospital, Tokyo Women's Medical University, Tokyo, Japan.
6.General Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Abstract

OBJECTIVE:

Plasma cancer antigen (CA)-125 is a tumour marker recently shown to be associated with systolic heart failure and new-onset atrial fibrillation (AF) after myocardial infarction. However, no reports have described the relationship between CA-125 and new-onset AF in healthy postmenopausal women. The aim of the present study was to evaluate the relationship between CA-125 and new-onset AF in postmenopausal women.

METHODS:

Between 2005 and 2015, 2086 women, including 1012 postmenopausal women, visited our hospital for annual health check-ups. We excluded patients with systolic dysfunction, chronic inflammatory disease, chronic obstructive pulmonary disease, histories of AF or neoplastic diseases. A total of 746 postmenopausal women underwent thorough physical examinations, including those for biomarkers such as brain natriuretic peptide, high-sensitivity C-reactive protein (hs-CRP) and CA-125.

RESULTS:

During the 10-year observation period, AF was documented in 31 participants (4.2%). The mean age of participants developing AF (75±6 years) was higher than that of those without AF (68±8 years). Participants developing AF showed significantly higher CA-125 (11.4±6.3 U/mL) and hs-CRP (0.10±0.11 mg/dL) levels than did those without AF (7.7±3.2 U/mL, p<0.01; 0.07±0.08 mg/dL, p<0.05). Cox regression analyses revealed ageing (HR 1.3; 95% CI 1.08 to 1.57; p<0.01) and plasma CA-125 levels (HR 1.29; 95% CI 1.10 to 1.51; p=0.02) as independent predictors of AF.

CONCLUSIONS:

High CA-125 levels might be associated with new-onset AF in healthy postmenopausal women.

資料來源 : PubMed



瀏覽次數: 567

Untitled Document